A humanized anti-HER2 monoclonal antibody that binds HER2 domain II and blocks HER2/HER3 dimerization.
Humanized anti-HER2 monoclonal antibody that binds HER2 extracellular domain II, blocks HER2/HER3 dimerization, inhibits downstream PI3K/AKT and MAPK signaling to suppress tumor cell proliferation and survival; can also mediate Fc-dependent ADCC.
Pertuzumab binds HER2 on target cells and engages Fcγ receptor–bearing immune cells to mediate ADCC, killing HER2+ cells; HER2/HER3 signaling blockade can also induce apoptosis.
Trop-2–directed antibody–drug conjugate with a topoisomerase I inhibitor payload.
Trop-2–targeted monoclonal antibody delivers the topoisomerase I inhibitor payload SN-38 to Trop-2–expressing tumor cells; after internalization and linker cleavage, SN-38 stabilizes topo I–DNA complexes, causing DNA breaks, replication arrest, and apoptosis (with potential bystander effect from released SN-38).
The ADC binds TROP2 on target cells, is internalized, and releases the SN-38 payload, a topoisomerase I inhibitor, causing DNA damage and apoptosis (with possible bystander killing from released SN-38).
Anti-CD2 monoclonal antibody that depletes/modulates CD2+ T and NK cells and interferes with T-cell co-stimulation/adhesion.
Humanized anti-CD2 monoclonal antibody that binds CD2 on T and NK cells, blocks CD2–LFA-3 co-stimulation/adhesion, and depletes/modulates CD2+ lymphocytes via Fc-mediated effector functions (ADCC/CDC), thereby suppressing T-cell activation and proliferation.
The anti-CD2 antibody binds CD2 on T/NK cells and engages Fc effector functions, causing NK cell–mediated ADCC and complement-dependent cytotoxicity (CDC), with possible apoptosis of CD2+ cells.
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
ATG antibodies bind CD2 on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytosis by effector cells, depleting CD2+ cells.
Polyclonal antilymphocyte/antithymocyte globulin that depletes T cells.
Polyclonal anti–T-lymphocyte immunoglobulin that binds multiple T‑cell surface antigens and induces complement-dependent cytotoxicity and Fc-mediated clearance (ADCC/phagocytosis), leading to rapid T‑cell depletion and immunosuppression.
ATG antibodies bind CD3ε on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance, leading to direct T-cell depletion.